Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

Overview of attention for article published in Clinical Epigenetics, January 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 29 Dimensions

Readers on

mendeley: 31 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 6,493 followers.

A 📝 by @PittIMChiefs @RyanAugustinMD & colleagues found a combination of pembrolizumab & azacitidine is safe & tolerable with modest clinical activity in the treatment for chemotherapy-refractory metastatic colorectal cancer. Available in @OA

14 Jan 2022

Reply Repost Favourite

Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis https://t.co/J9xMXSm39P https://t.co/d3v0qvmkRm

07 Jan 2022

Reply Repost Favourite

New article: Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis https://t.co/j1KtHRX6H5 #colorectalcancer #oncology https://t.co/s9CXuyqXM7

07 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.